Conceivable Life Sciences raises $50M in funding to bring robotic IVF embryo lab to US

For decades, in-vitro fertilization has relied on human hands and eyes—delicate, repetitive work that carries a high degree of variability. Conceivable Life Sciences wants to change that. The fertility tech startup just closed a $50 million Series A funding to bring its AI-powered automated IVF laboratory to clinics across the U.S., with its commercial debut set for next year.

The round was led by Advance Venture Partners (AVP) with backing from ARTIS Ventures, Stride, and ACME, bringing Conceivable’s total funding to $70 million since its $20 million seed round in late 2022. Bloomberg, which first reported the raise, described the company’s tech as “a robotic lab that can create human embryos,” adding that Conceivable plans to make it available at IVF clinics in the U.S. in early 2026.

The company’s platform, called AURA, automates more than 200 steps involved in IVF. Instead of relying on manual, artisanal processes, the system uses robotics and AI algorithms to bring precision and consistency to embryo creation. Conceivable’s team believes this approach could improve pregnancy outcomes, reduce costs, and expand access to a therapy still out of reach for many families.

“This funding validates our vision of transforming IVF through AI-powered robotic automation,” said Alan Murray, co-founder and CEO of Conceivable. “Our platform addresses the core challenges facing fertility clinics today —unpredictable success rates, capacity constraints, and accessibility barriers. This investment allows us to accelerate our bringing this groundbreaking technology to market.”

Conceivable is already running a 100-patient pilot study, with promising early results. “Ongoing pregnancy results from the current trial are quite positive and we have 18 healthy babies from an earlier study on prototype instruments,” said Dr. Alejandro Chavez-Badiola, reproductive endocrinologist, co-founder, and Chief Medical Officer. “Early indications from clinical KPIs are very promising and demonstrate that robotic precision and AI-driven protocols will outperform traditional manual approaches. We are committed to delivering consistent outcomes that fertility patients deserve.”

AI Meets Fertility: Conceivable Life Sciences Secures $50M to Launch World’s First AI-Powered Automated IVF Lab

Demand for IVF is climbing, but supply remains limited. Experts estimate the unmet demand for IVF is ten times higher than what current clinics can handle. Add high costs to the equation, and many patients are shut out. Conceivable believes automation can help solve those bottlenecks—standardizing procedures, improving results, and making treatment more affordable.

“The fertility industry stands at a critical inflection point where breakthrough innovation will fundamentally expand access to care,” said Alex Christ, General Partner at Advance Venture Partners. “We saw a fragmented landscape of companies building low-impact, point solutions for individual IVF processes, but only Conceivable tackling the full end-to-end approach to IVF that truly pushes the industry forward. By integrating these complex steps in one system, they’ve revolutionized the IVF lab with technology, engineering, and biology at the core. Conceivable’s technology will enable the entire sector to deliver fertility care that’s more consistent, scalable, and – most importantly – within reach for the families who need it most.”

Founded in 2014, Conceivable has spent years building a platform that blends automation, optics, robotics, and AI to bring consistency to IVF. The company describes its mission as shifting a Nobel Prize-winning therapy from being a luxury service for the few to a population-level health solution available to many.